Forecast Period | 2026-2030 |
Market Size (2024) | USD 1.74 billion |
Market Size (2030) | USD 2.37 Billion |
CAGR (2025-2030) | 5.45% |
Fastest Growing Segment | Reagent |
Largest Market | North India |
Market Overview
India In Vitro Diagnostics Market was valued at USD 1.74 billion in 2024 and is expected to reach USD 2.37 Billion by 2030, with a CAGR of 5.45% during the forecast period.
In-vitro diagnostics (IVD) refer to medical tests performed on samples such as blood, urine, or tissue outside the human body, typically in laboratory settings. These tests are essential for diagnosing diseases, detecting infections, and monitoring treatment outcomes, providing critical data for effective healthcare management.
IVD plays a vital role in identifying conditions like diabetes, infections, and genetic disorders, while also supporting continuous monitoring for patients with chronic diseases. The growing elderly population in India further increases the need for regular diagnostic testing.
Advancements in technologies such as AI integration and point-of-care devices are expanding diagnostic capabilities and accessibility. Additionally, the rise of precision medicine and the growth of the pharmaceutical and biotechnology sectors are driving demand for specialized diagnostic tests.
Government initiatives like the National Health Mission and Ayushman Bharat are also improving healthcare access and affordability, further supporting the expansion of the IVD market in India.
Key Market Drivers
Technological Advancements
Technological advancements are reshaping India’s IVD landscape by moving diagnostics beyond conventional pathology into faster, more precise, and more patient-friendly formats that can support everything from infectious disease detection to oncology profiling and long-term disease management, and this shift is becoming especially visible as leading diagnostic networks invest in molecular diagnostics, next generation sequencing, artificial intelligence, digital pathology, and smart reporting systems that improve turnaround time while also helping clinicians interpret increasingly complex data with greater confidence.
In India, this transition matters because large organized laboratory chains are no longer relying only on routine biochemistry and microscopy but are building differentiated capability in specialized and semi-specialized testing, supported by strong laboratory infrastructure, accredited facilities, and digital systems that can sustain scale across urban and non-urban markets.
For instance, Metropolis Healthcare stated in its FY 2023-24 annual report that it integrated Molecular Genomics, Artificial Intelligence, and Next Generation Sequencing through its Innovation Cell, launched over 100 advanced tests during the year, operated 199 clinical laboratories and a service network of 4,150 points, and served more than 600 towns in India, showing that advanced IVD technologies are already being deployed at significant commercial scale rather than remaining limited to niche tertiary centres.
As these technologies expand into broader clinical use, they directly raise demand for IVD reagents because each new molecular panel, immunoassay workflow, automated analyzer, or digitally enabled testing pathway depends on a steady supply of validated consumables that can deliver consistent performance across high-volume settings.
Growing Aging Population
India’s growing elderly population is becoming an increasingly important demand driver for the IVD market because older adults are far more likely to need recurring diagnostic support for diabetes, cardiovascular conditions, cancers, kidney disorders, infections, and multiple coexisting health issues that require regular screening, follow-up, and treatment monitoring rather than occasional one-time testing, and this demographic transition is now large enough to reshape how healthcare delivery and diagnostics are planned across the country.
Official government data notes that the population aged 60 years and above is projected to more than double from 100 million in 2011 to 230 million by 2036, nearly one in seven Indians is expected to be 60 years or older by then, and the Longitudinal Ageing Study of India found that elderly people already account for 12 percent of the population with this number projected to rise to 319 million by 2050.
For instance, Metropolis Healthcare reported 12 million patient volumes in FY 2023-24, a network of 199 laboratories, more than 4,150 service points, and specially curated wellness packages for screening lifestyle and chronic diseases, illustrating how large diagnostic companies in India are positioning their test menus and access networks to meet the sustained monitoring needs that typically rise with age.
This trend is likely to keep strengthening because elderly patients often require repeat blood chemistry, cancer markers, pathology review, infection testing, and treatment-response assessment, while government-backed geriatric healthcare expansion and wider insurance access are making diagnostic utilization more frequent and more structured across India’s aging population.
Download Free Sample Report
Key Market Challenges
Price Sensitivity
Price sensitivity remains a major challenge in India’s IVD market because diagnostic spending still competes with household budget constraints, especially in a system where out-of-pocket payments continue to account for a large share of healthcare expenditure even after recent policy efforts to reduce the burden on patients.
The Ministry of Health and Family Welfare has stated that out-of-pocket expenditure fell from 62.6 percent of total health expenditure in 2014-15 to 39.4 percent in 2021-22, yet independent research published in Frontiers also notes that diagnostics, medicines, and medical devices together make up nearly half of household out-of-pocket healthcare spending in India, which means test affordability still strongly influences whether patients choose advanced assays, basic panels, or defer testing altogether.
This pressure is intensified by a fragmented diagnostics landscape where large branded chains, hospital laboratories, regional players, and online aggregators all compete for the same consumer by emphasizing discounts, bundled packages, and lower realization per test rather than premium pricing alone.
For instance, CARE Ratings reported that Dr. Lal PathLabs had a network of 280 clinical labs, 5,762 patient service centres, and 11,619 pick-up points as of March 31, 2024 and was expected to test more than 2.8 crore patients and over 8.7 crore samples in FY25, yet the same report highlighted intense competition from numerous players and online aggregators offering discounts, showing that even the largest organized companies in India must keep affordability at the centre of their strategy.
As a result, cost considerations continue to shape test adoption across regions, with patients in lower-income and semi-urban markets often preferring routine or essential diagnostics over specialized panels unless the clinical need is urgent or strongly physician-led..
Quality Control and Standardization
Quality control and standardization remain critical challenges in India’s IVD market because regulation exists but quality assurance still depends on how consistently licensing, accreditation, validation, and laboratory practices are implemented across a highly diverse ecosystem of manufacturers, importers, standalone laboratories, hospital labs, and diagnostic chains.
The CDSCO states that in vitro diagnostic medical devices in India are regulated under the Drugs and Cosmetics Act and the Medical Devices Rules, 2017, while its official guidance also shows that responsibilities are split between the Central Licensing Authority and State Licensing Authorities for import, manufacture, clinical performance evaluation, and enforcement, which can create uneven execution if capabilities differ across jurisdictions.
At the quality systems level, NABL says its accreditation framework aligns with international standards such as ISO 15189 and ISO 17025 and is linked to global recognition arrangements through ILAC and APAC, so accreditation acts as an important benchmark for analytical reliability, process discipline, and comparability of results.
For instance, CARE Ratings reported that Dr. Lal PathLabs operated 280 clinical labs as of March 31, 2024 and that 40 of its labs were accredited by NABL while two were accredited by the College of American Pathologists, demonstrating how leading companies use formal accreditation to signal quality but also indicating that standardization is an ongoing operational effort rather than an automatic industry-wide condition.
In a market where CARE also notes fragmented competition and the absence of stringent government regulations as a rating concern, strengthening uniform quality protocols, technician competency, infrastructure discipline, and wider accreditation coverage will remain essential for building trust in test accuracy and supporting long-term growth in India’s diagnostics sector..
Key Market Trends
Rise in Home Testing
Home testing is emerging as a key trend in India’s IVD market, driven by convenience, privacy, and improved accessibility. It eliminates the need for travel and long wait times, while offering a discreet option for sensitive health tests.
It also enhances access to diagnostics in remote and underserved areas, supporting broader healthcare reach. With rising health awareness, individuals are increasingly adopting home testing for preventive care and regular monitoring of key health parameters.
For chronic conditions like diabetes, home testing enables frequent and efficient tracking, improving disease management. The growth of telemedicine and advancements in point-of-care devices further support this trend by enabling quick, reliable testing and remote consultation. Overall, home testing is empowering patients and expanding the scope of decentralized diagnostics in India.
Rising Pharmaceutical and Biotech Industry
IVD plays a critical role in pharmaceutical and biotech R&D by supporting drug discovery, development, and clinical trials. Diagnostic tests help identify therapeutic targets, screen and monitor patients, and assess drug safety and efficacy.
Companion diagnostics are key to precision medicine, enabling targeted therapies based on individual patient profiles. IVD also supports biomarker identification, pharmacogenomics, and therapeutic drug monitoring, improving treatment outcomes and minimizing side effects.
Additionally, IVD is essential for quality control in manufacturing and for tracking infectious diseases to guide vaccine and treatment development. The use of point-of-care devices further accelerates research by enabling rapid, on-site testing. Overall, growing reliance on advanced therapies such as immunotherapy and gene therapy is increasing the importance of IVD in pharma and biotech innovation.
Segmental Insights
Product Insights
Based on Product, Reagent segment is anticipated to demonstrate the fastest growth in the India In Vitro Diagnostics Market through 2030. Reagents are essential
components in a wide range of diagnostic tests, from basic blood tests to
complex molecular diagnostics. As the demand for diagnostic testing continues
to grow in India, the need for reagents to conduct these tests also increases. Reagents
are used in various diagnostic disciplines, including clinical chemistry,
hematology, immunology, microbiology, and molecular diagnostics. This diversity
of applications ensures a broad customer base, contributing to the significant
market share of the reagent segment.
Many routine diagnostic tests, such as
blood glucose, cholesterol, and liver function tests, require reagents. These
tests are conducted frequently in healthcare settings, driving consistent
demand for reagents. Reagents play a crucial role in the monitoring and
management of chronic diseases like diabetes and cardiovascular conditions.
With the increasing prevalence of such diseases in India, there is a steady
requirement for reagents used in disease monitoring. Reagents are fundamental
in diagnosing and monitoring infectious diseases, including viral and bacterial
infections. The need for infectious disease testing, especially in the context
of public health and the ongoing COVID-19 pandemic, contributes to the high
demand for reagents.
Application Insights
In 2024, the India In Vitro Diagnostics Market
largest share was held by Diabetes segment and is predicted to continue
expanding over the coming years. India has one of the
highest rates of diabetes in the world. The country is experiencing an epidemic
of both type 2 diabetes and, to a lesser extent, type 1 diabetes. This high
prevalence of diabetes naturally drives the demand for diagnostic tests to identify
and monitor the condition. The incidence of diabetes in India continues to rise
due to factors such as sedentary lifestyles, poor dietary habits, and genetic
predisposition.
As more people are diagnosed with diabetes, the demand for
diabetes-related diagnostic tests increases. Diabetes is a chronic condition
that requires regular monitoring of blood glucose levels to manage the disease
effectively. IVD tests, such as blood glucose monitors and HbA1c tests, are
essential for assessing and controlling diabetes. Early detection of diabetes
and prediabetic conditions is critical for preventing the progression of the
disease and its complications. Routine screening and diagnostic tests play a
crucial role in identifying individuals at risk. Growing awareness about
diabetes and its associated health risks has led to more individuals seeking
diagnostic testing to assess their diabetes status. Healthcare campaigns and
education programs have contributed to this increased awareness.
Download Free
Sample Report
Regional Insights
North India dominates the Indian in vitro diagnostics market in 2024. North India is home to some of the most densely populated states in
the country, including Uttar Pradesh, Bihar, and Haryana. High population density results in a larger pool of potential patients and consumers for IVD
products and services. The North Indian states, particularly the National
Capital Region (NCR), have relatively better healthcare infrastructure compared
to some other regions. This includes a higher concentration of hospitals,
clinics, and diagnostic laboratories that use IVD products. North India, with
its major cities like Delhi, Gurugram, and Noida, is a hub of economic
activity. This leads to greater healthcare expenditure, including diagnostics,
among the urban and semi-urban population.
Recent Developments
- In November 2025, Servier India partnered with MedGenome and Strand Life Sciences to launch a biomarker-testing initiative for acute myeloid leukaemia and cholangiocarcinoma patients in India. The collaboration expanded access to advanced molecular diagnostics by offering customized IDH1 and IDH2 testing panels at subsidized rates, including free testing for patients in the government healthcare system.
- In September 2025, India’s health authorities introduced a new IVD validation portal and standardized analytical and clinical validation protocols through the joint work of ICMR and CDSCO at the VRDL Conclave 2025. The government said the portal would allow manufacturers to submit and track validation applications digitally, while the common protocols were designed to improve transparency, consistency, and quality assessment across diagnostic products in India.
- In February 2025, GOQii and Acrannolife Genomics launched GrafCare, a post-transplant digital care program that combines GOQii’s connected health monitoring with Acrannolife’s Trunome genomic diagnostics platform. The launch was positioned as a precision-health innovation for transplant patients because it linked molecular testing for early rejection or infection risk with AI-enabled tracking and follow-up care in a single program.
Key Market Players
- Abbott
India Limited
- Danaher
(DHR) Holding India Pvt Limited
- Roche
Diagnostics India Pvt. Ltd.
- bioMérieux
India Private Limited
- Transasia
Bio-Medicals Ltd.
- bioMérieux
India Limited
- Becton
Dickinson Private Limited
- Thermo
Fisher Scientific India Pvt. Ltd.
- Siemens
Healthcare Private Limited
- Sysmex
India Pvt. Ltd
|
By Product
|
By Test Type
|
By Usability
|
By Application
|
By End User
|
By Region
|
|
|
- Clinical
Chemistry
- Molecular
Diagnostics
- Hematology
- Immuno
Diagnostics
- Other
|
- Disposable
In Vitro Diagnostics Devices
- Reusable
In Vitro Diagnostics Devices
|
- Infectious
Disease
- Diabetes
- Oncology
- Cardiology
- Autoimmune
Disease
- Nephrology
- Others
|
- Diagnostic
Laboratories
- Hospitals
& Clinics
- Others
|
- North
America
- Europe
- Asia
Pacific
- South
America
- Middle
East & Africa
|
Report
Scope:
In this report, the India In Vitro Diagnostics
Market has been segmented into the following categories, in addition to the
industry trends which have also been detailed below:
- India In Vitro Diagnostics Market, By
Product:
o Instrument
o Reagent
o Other
- India In Vitro Diagnostics Market, By Test
Type:
o Clinical Chemistry
o Molecular Diagnostics
o Hematology
o Immuno Diagnostics
o Other
- India In Vitro Diagnostics Market, By
Usability:
o Disposable In Vitro Diagnostics
Devices
o Reusable In Vitro Diagnostics
Devices
- India In Vitro Diagnostics Market, By
Application:
o Infectious Disease
o Diabetes
o Oncology
o Cardiology
o Autoimmune Disease
o Nephrology
o Others
- India In Vitro Diagnostics Market,
By End-User:
o Diagnostic Laboratories
o Hospitals & Clinics
o Others
- India In Vitro Diagnostics Market, By region:
o North India
o South India
o East India
o West India
Competitive Landscape
Company Profiles: Detailed
analysis of the major companies presents in the India In Vitro Diagnostics
Market.
Available Customizations:
India In Vitro Diagnostics Market
report with the given market data, TechSci Research offers customizations
according to a company's specific needs. The following customization options
are available for the report:
Company Information
- Detailed analysis and profiling of
additional market players (up to five).
India In Vitro Diagnostics
Market is an upcoming report to be released soon. If you wish an early delivery
of this report or want to confirm the date of release, please contact us
at [email protected]